Tag - Astrocyte Pharmaceuticals

Game On for Concussion Therapies

Antonette Ho2024-03-10T00:44:19-05:00Most concussions—mild traumatic brain injuries (TBIs)—aren’t treated. Only a fraction of people who experience concussions seek help, and those who do usually are only prescribed rest. For about 20 percent, however, rest doesn’t alleviate the symptoms. Those symptoms may persist for months or years, making daily life difficult. As yet, there is no FDA-approved treatment for mild TBI. A few companies are addressing this increasingly-acknowledged problem by developing treatments that actually target the injury itself rather than just the resulting...

Alzheimer’s Drug Discovery Foundation Joins Astrocyte Pharmaceuticals’ $6M Pre-Series B Financing Round to Expand Development of Cerebroprotectant AST-004

Antonette Ho2023-08-23T00:52:36-04:00Astrocyte Pharmaceuticals Inc., a clinical-stage drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, announced an oversubscribed pre-Series B Bridge financing round of over $6M that was led by Dreavent Capital, and joined by the Alzheimer's Drug Discovery Foundation, and other investors. The funding will accelerate the clinical development of AST-004, a highly promising therapeutic candidate aimed at treating a broad array of acute brain injuries including stroke and traumatic brain injury (TBI), and further...

Astrocyte Pharmaceuticals Announces Theodore Liston, Ph.D., Vice President of Research, as Recipient of the 2022 Innovation and Progress Award from the Journal Stroke

Antonette Ho2023-04-17T00:32:49-04:00Astrocyte Pharmaceuticals Inc., a private drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, today announced that Theodore Liston, Ph.D., Vice President of Research at Astrocyte, received the 2022 Progress and Innovation Award from the journal Stroke for authoring one of the journal’s top three publications in 2022. The Innovation and Progress Award recognizes research that demonstrates “a new approach, new methodology, new interpretation of existing data, or new data with far-reaching implications.” Dr. Liston’s...

Astrocyte Announces Initiation of an Extended Infusion Phase 1B Study of AST-004 for Stroke and Traumatic Brain Injuries

Antonette Ho2023-04-13T10:24:37-04:00Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, is pleased to announce the initiation of a Phase 1B study of its lead candidate, AST-004, as an extended infusion in healthy volunteers. This adaptive-design clinical study will be conducted over the next four to six months at the QPS clinical research site in Groningen, Netherlands. AST-004 is a small molecule adenosine A3/A1 receptor agonist that has consistently shown promising cerebroprotective results...

Astrocyte Pharmaceuticals Presents Update on AST-004 Clinical Program at 2022 Military Health System Research Symposium

Ziad2022-11-25T13:59:44-05:00Astrocyte Pharmaceuticals Inc., a private drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, today provided an update on the preclinical and clinical development of its lead drug candidate, AST-004, in preclinical brain injury studies and in an ongoing clinical Phase 1 study. Theodore Liston, Ph.D., Vice President of Research at Astrocyte, presented recent results during an oral session at the U.S. Defense Department's premier scientific meeting, the Military Health System Research Symposium (MHSRS) held...

Astrocyte Announces Initiation of First-In-Human Phase 1 Study of the Promising Stroke and Traumatic Brain Injury Therapeutic, AST-004

Ziad2022-11-25T13:59:45-05:00Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, announced that the Company’s first-in-human Phase 1 clinical study initiated today with the dosing of a first subject with AST-004. The promising investigational therapeutic, AST-004, is being advanced as a potential acute treatment for stroke and traumatic brain injury (TBI) victims, and as a chronic treatment for neurodegenerative diseases like Alzheimer’s. AST-004 has demonstrated a broad range of cerebroprotective efficacy when treating...

Astrocyte Pharmaceuticals Announces Appointment of Christine Gallagher to Board of Directors

Ziad2022-11-25T14:00:10-05:00Astrocyte Pharmaceuticals Inc., a drug discovery and development company developing novel cerebroprotective therapeutics for patients with brain injuries, announced today that Christine Gallagher has joined the company’s Board of Directors. Ms. Gallagher has over 30 years of experience as an investment banker focused on the life sciences industry. She is currently Managing Director, Equity Capital Markets at Truist Securities (formerly SunTrust Robinson Humphrey) where she is directly responsible for leading the planning, structuring and execution of equity capital raises for...

CT Biotech Firm Working Drug to Treat Stroke, Brain Injuries

Ziad2022-11-25T14:00:10-05:00Co-founded by William Korinek of Stonington, who spent nearly a decade at Pfizer, Astrocyte Pharmaceuticals expects to launch a phase one clinical trial of its leading drug candidate in the first half of 2022. Last week, Astrocyte put out word that Stroke, a peer-reviewed journal, had published the results of preclinical studies of the drug, known for now as AST-004. The lack of available treatments for stroke is a major unmet medical need, one that could qualify Astrocyte’s drug development...

Groton biotech firm working on much-needed drug to treat stroke, brain injuries

Ziad2022-11-25T14:00:10-05:00A small drug development company that moved its headquarters from Cambridge, Mass., to the BioCT Innovations Commons on Shennecossett Road last year is aiming to have a huge impact on the treatment of strokes and brain injuries. Co-founded by William Korinek of Stonington, who spent nearly a decade at Pfizer, Astrocyte Pharmaceuticals expects to launch a phase one clinical trial of its leading drug candidate in the first half of 2022. Read more >>

Astrocyte Pharmaceuticals Announces Publication in the Journal Stroke of Results Supporting Advancement of AST-004 into in the Clinic

Ziad2022-11-25T14:00:11-05:00Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of brain injuries, today announced the publication of a manuscript in the peer reviewed journal Stroke entitled: Adenosine A1R/A3R (Adenosine A1 and A3 Receptor) Agonist AST-004 Reduces Brain Infarction in a Nonhuman Primate Model of Stroke. The manuscript describes the results of pre-clinical studies using AST-004, Astrocyte’s lead drug candidate, for the treatment of stroke. Read more >>